IAM-LC vs LEKC for Pulmonary Drug Permeability

Predicting whether a drug can cross the respiratory mucosa requires more than a conventional lipophilicity measurement. Biological membranes contain phospholipids, carry local charges, and interact with ionised compounds in ways that are not fully represented by the standard n-octanol/water system. The reference study, published in Journal of Chromatography A on 11 October 2024, evaluates two biomimetic chromatographic approaches as alternatives: immobilised artificial membrane liquid chromatography (IAM LC) and liposome electrokinetic capillary chromatography (LEKC). Its central contribution is a direct, comparative assessment of how well each technique represents drug–membrane partitioning and apparent pulmonary permeability.

The analysis is relevant to respiratory disease research because permeability data can inform compound selection, formulation studies, and interpretation of exposure across the airway barrier. However, the study is a physicochemical and chromatographic investigation; it does not itself establish anti-inflammatory efficacy or clinical performance.

Study Background and Research Question

Lipophilicity and solubility influence absorption after enteral, parenteral, and pulmonary administration. The neutral-form partition coefficient, usually expressed as log P_o/w, is commonly measured with n-octanol and water. For weak acids and bases, log D at a defined pH is often more informative because it reflects the mixture of ionised and non-ionised species. The reference study explains that this conventional system remains a simplified surrogate for a biological membrane, particularly when electrostatic interactions between charged drugs and phospholipid headgroups are important. These principles and the study rationale are described in the reference article.

IAM LC uses a stationary phase containing immobilised phospholipid-like groups, while LEKC uses liposomes in an electrokinetic capillary format to model dynamic interactions with phospholipid assemblies. The research question was therefore practical and comparative: does either biomimetic method provide a more useful representation of pulmonary drug permeability, and what trade-offs arise in compound coverage, interpretability, and laboratory implementation?

Key Innovation from the Reference Study

The innovation lies in comparing IAM LC and LEKC within a common set of structurally unrelated drug-like molecules rather than evaluating each method in isolation. The investigators studied 26 compounds and related chromatographic retention parameters to conventional partitioning metrics and experimentally determined apparent lung permeability. This design allows the two techniques to be judged not only by their correlation with log P or log D, but also by how well they predict a biologically relevant pulmonary transport endpoint.

A second important advance is the explicit treatment of phospholipid charge. LEKC experiments included liposome systems containing phosphatidylcholine and phosphatidylinositol, enabling the analysis to consider both hydrophobic association and electrostatic attraction or repulsion. This is mechanistically different from n-octanol/water partitioning and helps explain why relationships with distribution coefficients were not always simple linear trends. The study’s comparative findings are reported in the open-access reference study.

Methods and Experimental Design Insights

The experimental strategy combined chromatographic retention measurements with external physicochemical and permeability descriptors. IAM LC generated a hydrophobicity index, identified as CHI_IAM. LEKC generated logarithmic distribution or retention constants that reflected the interaction of test compounds with liposome-containing systems. These outputs were compared with log P_o/w for neutral compounds, log D at pH 7.4, and experimental apparent lung permeability.

This structure is useful for assay development because it separates three questions that are often conflated: whether a compound partitions into a membrane-like phase, whether its ionisation state changes that interaction, and whether the resulting parameter tracks pulmonary barrier passage. The study also tested more than one liposome composition and concentration, allowing the investigators to examine whether the biological mimic itself changes the observed relationship.

Protocol Parameters

• Compound panel: 26 structurally unrelated drug-like molecules were assessed using both biomimetic chromatographic approaches, as described in the reference study.
• IAM LC readout: Retention was converted into the CHI_IAM hydrophobicity index for comparison with partition and distribution coefficients.
• LEKC readout: Liposome-associated retention or distribution constants were expressed logarithmically and evaluated against the same reference descriptors.
• Experimental pH: Distribution behavior was examined at pH 7.4, a condition that exposes the effect of ionisation on membrane-like interactions.
• Liposome composition: LEKC included phosphatidylcholine:phosphatidylinositol mixtures at 85:15 and 90:10 molar ratios; a 4 mM liposome condition was also examined in the reported comparisons.
• External benchmarks: Neutral-form log P_o/w, pH-dependent log D_7.4, and apparent lung permeability were used as comparison endpoints rather than treating any single chromatographic measurement as a complete permeability model.

For researchers adapting the workflow, the study supports measuring both neutral and ionisation-sensitive descriptors where possible. It also suggests that liposome composition should be treated as an experimental variable, not merely as a reagent detail, because charged phospholipids can alter the apparent interaction profile.

Core Findings and Why They Matter

IAM LC and most LEKC measurements showed moderate linear relationships with n-octanol/water partition coefficients for neutral molecular forms. This result indicates that both methods retain a substantial hydrophobicity component. It also confirms that biomimetic retention should not automatically be interpreted as a direct measurement of transmembrane passage; related but distinct physicochemical processes are being sampled.

The relationship with log D_7.4 was weaker for IAM LC overall. For some LEKC conditions, especially the phosphatidylcholine:phosphatidylinositol compositions and the 4 mM liposome systems, the relationship became sigmoidal rather than linear. This behavior is scientifically meaningful. It is consistent with a system in which charge-dependent interactions supplement hydrophobic partitioning, producing concentration- and composition-dependent responses that cannot be reduced to a single octanol-like scale.

The most consequential result concerned pulmonary permeability. LEKC retention parameters showed stronger associations with experimentally measured apparent lung permeability than IAM LC, with correlations exceeding R = 0.65 in the reported analysis. In practical terms, LEKC more effectively represented the combined hydrophobic and electrostatic forces that influence interaction with pulmonary membrane models. The numerical comparison and its interpretation should be read directly in the published study, because the correlation depends on the selected liposome conditions and compound set.

LEKC was not universally superior. Data could not be obtained for highly hydrophilic neutral or anionic compounds at the experimental pH. IAM LC covered a wider lipophilicity range and was described as simpler, more robust, and more amenable to automated high-throughput operation. The methods therefore serve different stages of drug development: IAM LC is attractive for broad screening, while LEKC may be more informative when pulmonary membrane interactions and ionisation effects are central to the question.

Comparison with Existing Internal Articles

The internal translational pulmonary research overview discusses biomimetic modeling in the context of broader respiratory workflows. Its practical orientation complements the reference study, but the current paper provides the stronger evidence for choosing between IAM LC and LEKC because it directly compares both platforms using the same molecular panel and permeability endpoint.

A separate asthma inflammation model guide focuses on biological responses and experimental workflow design. That resource is useful when planning airway inflammation or allergic inflammation inhibition studies, but it should not be interpreted as validation of the chromatographic results. The reference study does not test an asthma inflammation model, cytokine response, receptor activity, or treatment efficacy; its contribution is the characterization of membrane-partitioning and pulmonary-permeability surrogates.

Limitations and Transferability

The 26-molecule panel provides a valuable cross-method comparison, but it cannot represent the full chemical diversity of inhaled drug candidates. Correlations also do not establish causation. A stronger association between LEKC and apparent lung permeability indicates improved modeling under the reported conditions, not universal prediction across formulations, species, disease states, or epithelial barrier models.

LEKC has additional operational constraints. Hydrophilic neutral and anionic compounds may be difficult or impossible to quantify at pH 7.4, and the result can depend on liposome composition and concentration. IAM LC is less physiologically detailed, but its reproducibility and automation advantages may make it more suitable for early library screening. A staged workflow could therefore use IAM LC for broad characterization and LEKC for selected compounds whose charge-dependent pulmonary interactions require closer investigation.

Why this cross-domain matters, maturity, and limitations

Biomimetic chromatography and biological airway inflammation assays answer different questions. IAM LC and LEKC describe physicochemical interactions with membrane-like systems, whereas an airway inflammation experiment measures cellular signaling, tissue responses, or pharmacological modulation. Connecting the two domains can improve study design by separating permeability from efficacy, but the bridge remains conditional: each candidate still requires independent validation in an appropriate epithelial, cellular, or tissue model. The reference study supports the permeability side of that framework, not a claim of therapeutic activity.

Transferability is therefore strongest for comparative ranking within a defined assay system. Researchers should report pH, liposome composition, concentration, compound ionisation, and the specific permeability endpoint so that results can be interpreted across laboratories. The study’s main methodological lesson is not that one platform replaces the other, but that model selection should follow the chemical question and the intended biological barrier.

Research Support Resources

For related respiratory disease research, researchers can use Budesonide (SKU B1900), a high-purity anti-inflammatory corticosteroid and glucocorticoid receptor agonist, to support separate airway inflammation or asthma inflammation model workflows. The product information reports research-use-only status, storage at -20°C, and solubility in DMSO; these handling details should be checked before preparing experimental solutions. Because the reference study did not evaluate Budesonide, it should be used as a biological research reagent rather than treated as a validated result from the IAM LC or LEKC permeability comparison.